Scholarlink

Objectives <p>The prevalence of analgesic opioid (AO) misuse among patients with cancer-related chronic pain remains poorly understood, and no screening tool has been validated for this population. The Prescription Opioid Misuse Index (POMI), an eight-item self-administered questionnaire, was developed for chronic non-cancer pain. This study aimed to evaluate the psychometric properties of the POMI in a population of patients with chronic cancer-related pain.</p> Methods <p>This prospective observational psychometric study was conducted in two oncology day hospitals at the Clermont-Ferrand University Hospital. Eligible patients had active cancer, chronic pain lasting ≥ 3 months and were receiving daily opioid therapy. The POMI questionnaire was completed at inclusion (TEST) and 2 weeks later (RETEST). Psychometric properties were assessed following standard guidelines, including internal consistency, test–retest reliability and external validity using DSM-5 criteria for opioid use disorder as the reference standard.</p> Results <p>A total of 138 patients were included (58% men), with a mean age of 64 ± 10 years. Internal consistency of the POMI was low (Kuder–Richardson coefficient: 0.22). Test–retest reliability, assessed in 68 patients, showed moderate agreement (Lin’s concordance: 0.43 [0.24–0.63]). Correlation between POMI scores and DSM-5 criteria was modest (Spearman’s <i>ρ</i> = 0.25). According to the POMI, 11.6% of patients demonstrated opioid misuse versus 17.4% with DSM-5-defined use disorder.</p> Conclusions <p>The POMI lacks sufficient psychometric validity for use in oncology populations. Future tools should be specifically designed to address the clinical complexity and unique context of chronic cancer-related pain and opioid use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a multicenter study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月4日

查看全文
  • Virginie Guastella,
  • Mélanie Bianchi,
  • Eliane Hanniet,
  • Bruno Pereira,
  • Nicolas Authier

摘要

Objectives

The prevalence of analgesic opioid (AO) misuse among patients with cancer-related chronic pain remains poorly understood, and no screening tool has been validated for this population. The Prescription Opioid Misuse Index (POMI), an eight-item self-administered questionnaire, was developed for chronic non-cancer pain. This study aimed to evaluate the psychometric properties of the POMI in a population of patients with chronic cancer-related pain.

Methods

This prospective observational psychometric study was conducted in two oncology day hospitals at the Clermont-Ferrand University Hospital. Eligible patients had active cancer, chronic pain lasting ≥ 3 months and were receiving daily opioid therapy. The POMI questionnaire was completed at inclusion (TEST) and 2 weeks later (RETEST). Psychometric properties were assessed following standard guidelines, including internal consistency, test–retest reliability and external validity using DSM-5 criteria for opioid use disorder as the reference standard.

Results

A total of 138 patients were included (58% men), with a mean age of 64 ± 10 years. Internal consistency of the POMI was low (Kuder–Richardson coefficient: 0.22). Test–retest reliability, assessed in 68 patients, showed moderate agreement (Lin’s concordance: 0.43 [0.24–0.63]). Correlation between POMI scores and DSM-5 criteria was modest (Spearman’s ρ = 0.25). According to the POMI, 11.6% of patients demonstrated opioid misuse versus 17.4% with DSM-5-defined use disorder.

Conclusions

The POMI lacks sufficient psychometric validity for use in oncology populations. Future tools should be specifically designed to address the clinical complexity and unique context of chronic cancer-related pain and opioid use.